About Imviva
We are a clinical-stage biotechnology company leading the field of allogeneic CAR-T cell therapy. Our insights today advance our ultimate vision for the regenerative science of tomorrow.
Pushing the boundaries of cell therapy.
With a focus on oncology and autoimmune disease, we seek to create safer, more effective allogeneic CAR-T therapies designed to reach more patients in need. By delivering scalable, off-the-shelf and more potent cells at the point of care, we aim to reduce the barriers that limit access to cell therapy today.
Our progress is driven by elegant immune-evasion science and a disciplined, iterative approach to innovation. Through our growing pipeline — and beyond — we are expanding what cell therapy can achieve. Our vision is to use cells, tissues and organs to advance regenerative science — transcending traditional treatments and bringing to life new possibilities for medicine and health.
Our values
-
1
Innovation
We are dedicated to driving science and our industry forward, disrupting the status quo.
-
2
Agility
We work relentlessly with speed and adapt as needed to fulfill the promise of our science.
-
3
Perseverance
We pursue our goals with tenacity, iterating towards solutions and overcoming barriers with resolve.
Leadership team
Our leadership brings deep and broad expertise in cell therapy development, keeping us at the front of this cutting-edge field.
-
Jiangtao Ren, Ph.D.
Chief Scientific Officer
Learn More
-
Lu Han
Chief Executive Officer
Learn More -
Yajin Ni, MD, Ph.D.
Chief Technology Officer
Learn More -
Jan Davidson, MD, Ph.D.
Chief Medical Officer
Learn More -
Jay Yang, MD, Ph.D.
Vice President, Analytical Development & Quality Control (AD & QC)
Learn More -
Eileen M. McNulty
Vice President, Clinical Operations
Learn More -
Bo Pei, Ph.D.
Vice President, Research & Development
Learn More
Our path to the present.
-
Feb 2025
FDA Clearance of IND Application for CTD402 (our CD7 allo CAR-T) and obtained ODD, RPDD, RMAT after that -
Dec 2024
~$70M Series-B funded by Qiming, BioTrack, TruMed and others -
Apr 2024
Study result Sequential CD7 CAR T-cell Therapy and Allogeneic HSCT without GvHD prophylaxis published in The New England Journal of Medicine -
Mar 2021
~$80M Series-B funded by Hillhouse, Decheng & Octagon -
Feb 2019
~$20M Series-A funded by Decheng Capital -
May 2018
Angel financing by Simcere Pharma